{"id":"W4385667045","doi":"10.1097/01.hs9.0000970976.05785.80","title":"P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Discontinuation; Oncology; Gastroenterology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004255251,0.0009177077,0.002198654,0.0007634349,0.0003653095,0.001964359,0.001111303,0.001362325,0.008893696],"category_scores_gemma":[0.003815451,0.0003726528,0.002215375,0.001092319,0.0002692021,0.001116359,0.0006639647,0.002763618,0.00299031],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001409759,"about_ca_system_score_gemma":0.001370813,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001066629,"about_ca_topic_score_gemma":0.002781693,"domain_scores_codex":[0.9984015,0.0006038934,0.0002176064,0.0001566701,0.0004317462,0.0001886595],"domain_scores_gemma":[0.9957626,0.001047055,0.001357506,0.0002886937,0.0009475927,0.0005965346],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2033447,0.004815998,0.02543632,0.009965306,0.007034829,0.0007926253,0.0003224083,0.003026422,0.0248161,0.0006809841,0.2120584,0.5077059],"study_design_scores_gemma":[0.1501207,0.1182784,0.2532434,0.004242733,0.01921379,0.004196993,0.0002432163,0.002482456,0.0131589,0.001828292,0.4327066,0.0002844531],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5107746,0.1418498,0.004614095,0.01932475,0.004212292,0.00873356,0.2230951,0.001545329,0.08585056],"genre_scores_gemma":[0.6343258,0.04537039,0.007078312,0.02341464,0.004466104,0.006653444,0.2567703,0.0005209425,0.02140017],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008893696,"threshold_uncertainty_score":0.02975237,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02406813518054925,"score_gpt":0.296001022558554,"score_spread":0.2719328873780048,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}